WO2022096881A1 - Composition biocide - Google Patents

Composition biocide Download PDF

Info

Publication number
WO2022096881A1
WO2022096881A1 PCT/GB2021/052856 GB2021052856W WO2022096881A1 WO 2022096881 A1 WO2022096881 A1 WO 2022096881A1 GB 2021052856 W GB2021052856 W GB 2021052856W WO 2022096881 A1 WO2022096881 A1 WO 2022096881A1
Authority
WO
WIPO (PCT)
Prior art keywords
protease
biocidal composition
lipase
composition according
metalloprotease
Prior art date
Application number
PCT/GB2021/052856
Other languages
English (en)
Inventor
Martin Richards
Nicholas James HARMER
Original Assignee
Smarti Environmental Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smarti Environmental Limited filed Critical Smarti Environmental Limited
Priority to EP21806023.4A priority Critical patent/EP4240161A1/fr
Publication of WO2022096881A1 publication Critical patent/WO2022096881A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
    • A01N37/46—N-acyl derivatives
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/22—Phase substances, e.g. smokes, aerosols or sprayed or atomised substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/20—Targets to be treated
    • A61L2202/26—Textiles, e.g. towels, beds, cloths

Definitions

  • the present invention relates to a biocidal composition and to its use in protecting surfaces from microorganisms such as coronaviruses.
  • coronaviruses such as Covid- 19 persist on surfaces such as metal, wood, plastic, ceramics and glass for between two and five days, meaning there is an increased risk of a person coming into contact and subsequently becoming infected by the virus. While coronaviruses are readily disrupted by cleaning solutions such as bleach, ethanol, or detergents, these solutions do not provide surfaces with protection after the agent has been wiped down. Accordingly, there is an urgent need to protect surfaces against coronaviruses and other microorganisms for extended periods where surface cleaning cannot meet the rate at which the surface is touched by different people.
  • biocidal composition comprising:
  • At least one protease selected from a serine protease, a metalloprotease and a cysteine protease
  • the biocidal composition enables coronavirus levels on surfaces to be reduced by 99.9%. Moreover, it has been demonstrated that the biocidal composition is able to substantially eliminate coronaviruses from surfaces for a period of at least 16 hours after a single application of the biocidal composition to the surface. Therefore, the biocidal composition offers improved biocidal performance relative to existing cleaning solutions and only needs to be applied once daily as part of a regular cleaning routine. In particular, it has surprisingly been found that compositions comprising a mix of the claimed proteases and lipases exhibit improved coronavirus killing performance relative to compositions which comprise only one type of enzyme (protease or lipase).
  • the improved performance is due to the presence of the specific proteases and lipases in the composition which are able to respectively hydrolyse proteins and ester bonds in the lipid bilayer which envelops and protects coronaviruses; whereas other types or combinations of proteases and lipases may not have such efficacy.
  • the serine protease may comprise a subtilisin or alkaline protease.
  • the serine protease may comprise a subtilase.
  • the metalloprotease may be obtained from Bacillus subtilis.
  • the phospholipase may comprise a pancreatic phospholipase.
  • the biocidal composition may comprise at least two proteases and at least one lipase.
  • the biocidal composition may comprise a metalloprotease, a cysteine protease and a lipase.
  • the biocidal composition may comprise a metalloprotease, a cysteine protease and at least one lipase independently selected from the group comprising: a phospholipase, an esterase, and a microbial lipase.
  • the biocidal composition may comprise a metalloprotease, a cysteine protease and an esterase or microbial lipase.
  • Biocidal compositions comprising this combination of enzymes are particularly effective at eliminating coronaviruses at surfaces for extended periods of time.
  • the biocidal composition may comprise a pair of enzymes for hydrolysing proteins and ester bonds in the virus’ lipid bilayer.
  • the biocidal composition comprises one protease and one lipase.
  • the composition may comprise other enzymes, such as fragrance enzymes, which do not play a role in breaking down the virus’ lipid bilayer.
  • the biocidal composition may comprise a metalloprotease and an esterase or microbial lipase.
  • a biocidal composition comprising this combination of enzymes improved biocidal activity can be obtained over conventional cleaning solutions and over compositions that independently contain a metalloprotease or a lipase selected from esterase or microbial lipase.
  • the biocidal composition may comprise a cysteine protease and a lipase.
  • the biocidal composition may comprise a cysteine protease and a lipase independently selected from the group comprising: a phospholipase, an esterase, and a microbial lipase.
  • the biocidal composition may comprise a cysteine protease and an esterase or microbial lipase. Relative to conventional cleaning solutions, improved biocidal performance is obtained when a biocidal composition comprising this combination of enzymes is applied to a surface.
  • the biocidal composition may comprise a serine protease and an esterase or microbial lipase. Improved biocidal activity was obtained over conventional cleaning solutions and over compositions which independently contained a serine protease and an esterase or microbial lipase.
  • the biocidal composition may comprise a metalloprotease and a phospholipase, preferably a pancreatic phospholipase.
  • a metalloprotease and a phospholipase preferably a pancreatic phospholipase.
  • This combination of enzymes is effective at reducing coronavirus levels and exhibits improved performance relative to compositions comprising metalloproteases and phospholipases independently and relative to conventional cleaning solutions.
  • the biocidal composition may comprise cysteine protease and a phospholipase, preferably a pancreatic phospholipase.
  • This combination of enzymes is effective at reducing coronavirus levels and exhibits improved performance relative to compositions comprising cysteine proteases and phospholipases independently and relative to conventional cleaning solutions.
  • the biocidal composition may comprise a serine protease and a phospholipase, preferably a pancreatic phospholipase. This combination of enzymes exhibits improved biocidal activity over compositions which independently contain a serine protease and a phospholipase. Improved biocidal activity is also observed relative to known cleaning solutions without enzymes.
  • Each protease and lipase may be independently present in the composition at a concentration of between 0.001 and 1 %wt., preferably between 0.001 and 0.5 %wt. and more preferably between 0.001 and 0.1 %wt.
  • each enzyme is independently present in the composition at a concentration of between 0.001 %. and 0.5 %wt.
  • the protease may be present at a concentration of between 0.001 and 0.1 %wt. of the final composition; while the lipase may be present at a concentration of between 0.001 and 0.02 % wt, such as between 0.001 and 0.01 % wt. of the final composition.
  • the serine protease may be PROMOD 439L
  • the metalloprotease may be PROMOD 24L
  • the cysteine protease may be PROMOD 950L, all manufactured by Biocatalysts Limited, Unit 1, Cefn Coed, Parc Nantgarw, Cambridge, CF15 7QQ, Wales, UK.
  • the phospholipase may be LIPOMOD 699L or LIPOMOD 833L and/or the esterase may be LIPOMOD 34MDP all manufactured by Biocatalysts Limited, Unit 1, Cefn Coed, Parc Nantgarw, Cambridge, CF15 7QQ, Wales, UK.
  • PROMOD 24L, PROMOD 950L and LIPOMOD 34MDP PROMOD 24L and LIPOMOD 34MDP; PROMOD 950L and LIPOMOD 699L; PROMOD 24L and LIPOMOD 699L; PROMOD 24L, PROMOD 950L and LIPOMOD 699L; and PROMOD 950L and LIPOMOD 34MDP.
  • the composition may comprise a fragrance enzyme.
  • the composition may comprise 0.001 to 1 %wt. of metalloprotease, 0.001 to 1 %wt. of cysteine protease and 0.001 to 1 %wt. of esterase or microbial lipase.
  • the composition may comprise 0.001-0.5 %wt. of metalloprotease, 0.001-0.5 %wt. of cysteine protease and 0.001 - 0.5 %wt. of esterase or microbial lipase.
  • the composition may comprise 0.001-0.05 %wt. of metalloprotease; 0.001-0.1 %wt.
  • the biocidal composition may comprise a polymer derived from ethylene oxide.
  • the composition may comprise ethylene glycol.
  • ethylene glycol ethylene glycol
  • the biocidal composition may comprise at least one glycol ether of a C5-C15 alcohol, preferably of a CIO alcohol.
  • the CIO alcohol may be independently selected from the group comprising: 1-decanol and 2-propylheptanol.
  • the glycol ether may comprise at least one glycol ether independently selected from the group comprising: a polyethylene glycol-based glycol ether, a polypropylene glycol-based glycol ether, and a mixed polyethylene glycol and polypropylene glycol-based glycol ether.
  • the biocidal composition comprises a Deceth glycol ether, preferably Deceth-7.
  • the biocidal composition may comprise at least one isothiazolinone derivative.
  • the isothiazolinone derivative may be independently selected from the group comprising: methylisothiazolinone, chloromethylisothiazolinone, benzisothiazolinone, octylisothiazolinone, dichlorooctylisothiazolinone, and butylbenzisothiazolinone.
  • the biocidal composition comprises benzisothiazolinone.
  • the carrier may comprise a liquid, preferably the liquid comprises a disinfectant. It has been shown that the addition of enzyme mixtures to a known cleaning solution improves the effectiveness of the cleaning solution in eliminating coronaviruses from a surface.
  • the carrier may comprise an alcohol, suitably an ethanol- based alcohol. In particular, the alcohol may comprise 2-butoxy ethanol.
  • the carrier may comprise an acid, suitably a sulfonic acid.
  • the acid may comprise benzenesulfonic acid.
  • the acid may comprise a benzenesulfonic acid alkyl derivative, preferably a benzenesulfonic acid CIO- 14 alkyl derivative.
  • the carrier comprises an alcohol and an acid. Such a combination provides for effective delivery of the enzymes to a surface requiring disinfection to protect it for longer periods of time against microorganisms.
  • the carrier comprises at least one detergent.
  • the detergent may comprise one or more detergents independently selected from the group comprising: an anionic, cationic, zwitterionic, and non-ionic surfactant.
  • the detergent comprises an anionic detergent and/or a non-ionic detergent.
  • a carrier comprising detergents, and in particular anionic and/or non-ionic detergents, is believed to loosen up the structure of viral particles allowing the enzymes in the composition better access to virus particles.
  • the carrier comprises at least one glycol ether non-ionic detergent.
  • the glycol ether non-ionic detergent may comprise at least one glycol ether independently selected from the group comprising: a polyethylene glycol (PEG)-based glycol ether, a polypropylene glycol-based glycol ether, and a mixed polyethylene glycol and polypropylene glycol-based glycol ether.
  • the glycol ether non- ionic detergent preferably comprises a PEG-based glycol ether.
  • the glycol ether non- ionic detergent may comprise a glycol ether of a C5-C25 alcohol, preferably of a C8- C20 alcohol, more preferably of a C9-C15 alcohol, and most preferably of a C10-C13 alcohol.
  • the carrier comprises a glycol ether of a CIO and/or C13 alcohol.
  • the CIO alcohol may be independently selected from the group comprising: 1-decanol and 2-propylheptanol.
  • the C13 alcohol may preferably comprise 1 -tridecanol.
  • the glycol ether may comprise between 2-25 alkylene glycol units, more preferably between 3-20, 4-18, 5-16, 6-14, 7-12, or most preferably between 7-10 repeat units.
  • the carrier comprises a glycol ether with 7 or 10 alkylene glycol repeat units.
  • the carrier comprises a PEG-based glycol ether comprising a C5-C15 alkoxy group, C7-C14, C8-C14, C9-C13, or C10-C13 alkoxy group; and a PEG chain comprising between 3-15 PEG units, more preferably 5-10 PEG units, or most preferably 7-10 PEG units.
  • the carrier comprises a decyl glycol ether, preferably PEG-7 decyl ether.
  • the carrier comprises a tridecyl glycol ether, preferably PEG- 10 tridecyl ether.
  • the carrier comprises at least one alkyl anionic detergent or salts thereof, preferably an alkyl sulfate or phosphate or salts thereof, and most preferably an alkyl sulfate or salts thereof.
  • the carrier may comprise a C5-C25 alkyl sulfate, preferably a C6-C20, C7-C18, C8-C16, C9-C14, C10-C13, more preferably a C10-C12 alkyl sulfate, or most preferably lauryl sulfate, or salts thereof.
  • the carrier comprises an anionic detergent and a non-ionic detergent.
  • the carrier comprises an anionic detergent and a PEG-based glycol ether non-ionic detergent.
  • the PEG-based glycol ether is preferably as described above.
  • the PEG-based glycol ether may comprise a C5-C15 alkoxy group, C7-C14, C8-C14, C9-C13, or C10-C13 alkoxy group; and a PEG chain comprising between 3-15 PEG units, more preferably 5-10 PEG units, or most preferably 7-10 PEG units.
  • the carrier comprises a non-ionic detergent and an alkyl anionic detergent or a salt thereof.
  • the alkyl anionic detergent is preferably as described above.
  • the alkyl anionic detergent preferably comprises an alkyl sulfate or a salt thereof, preferably a C5-C25, C8-C16, or C10-C13 alkyl sulfate.
  • the alkyl anionic detergent comprises a lauryl sulfate or a salt thereof.
  • the carrier comprises at least one PEG-based glycol ether non-ionic detergent and an alkyl anionic detergent or salt thereof.
  • the carrier may comprise a PEG-based glycol ether with a C5-C15 alkoxy group and 3-15 PEG units, or a PEG-based glycol ether with a C8-C14 alkoxy group and 5-10 PEG units, or a PEG-based glycol ether with a C10-C13 alkoxy group and 7-10 PEG units; and an alkyl sulfate or salt thereof, preferably a C5-C25 alkyl sulfate or salt thereof.
  • the carrier may comprise a PEG-based glycol ether with a C5-C15 alkoxy group and 3-15 PEG units, or a PEG-based glycol ether with a C8-C14 alkoxy group and 5-10 PEG units, or a PEG-based glycol ether with a C10-C13 alkoxy group and 7- 10 PEG units; and a C8-C16 alkyl sulfate or salt thereof.
  • the carrier may comprise a PEG-based glycol ether with a C5-C15 alkoxy group and 3-15 PEG units, or a PEG-based glycol ether with a C8-C14 alkoxy group and 5-10 PEG units, or a PEG-based glycol ether with a C10-C13 alkoxy group and 7- 10 PEG units; and a C10-C13 alkyl sulfate or salt thereof, preferably a lauryl sulfate or salt thereof.
  • the carrier comprises PEG- 10 tridecyl ether and sodium lauryl sulfate.
  • Salts of the alkyl anionic detergent as described in the above statements may comprise an ammonium cation or a metal cation.
  • the metal cation may be independently selected from the group comprising: ammonium, sodium, potassium, lithium, and copper.
  • the carrier comprises at least one film-forming agent.
  • the film- forming agent may be independently selected from the group comprising: a polyvinylpyrrolidone, an acrylate, an acrylamide, a styrene, and combinations, blends or copolymers thereof.
  • the film-forming agent may be independently selected from: an acrylate, a styrene, and combinations, blends, or copolymers thereof.
  • the film- forming agent comprises a film-forming polymer.
  • the film-forming polymer may preferably comprise a polyacrylate and/or an acrylate copolymer.
  • the film-forming polymer comprises an acrylate-styrene copolymer.
  • film-forming agents When applied to a surface, such film-forming agents enable the enzymes and other actives in the biocidal composition to contact the surface for longer periods of time, enabling protection of the surface from microorganisms, particularly viruses, for > 16 hours.
  • the carrier comprises at least one detergent and at least one film-forming agent, preferably as described above.
  • the carrier may preferably comprise an anionic detergent and/or a non-ionic detergent, and at least one filmforming agent, preferably as described above.
  • the carrier comprises an anionic detergent, a non-ionic detergent, and at least one film-forming agent.
  • the carrier comprises at least one alkyl anionic detergent or a salt thereof, preferably an alkyl sulfate or salt thereof as described above; at least one glycol ether non-ionic detergent, preferably a PEG-based glycol ether as described above; and at least one film-forming agent, preferably a film-forming polymer as described above, and more preferably a polyacrylate and/or an acrylate copolymer.
  • the carrier comprises a lauryl sulfate or a salt thereof, PEG- 10 tridecyl ether, and an acrylate- styrene copolymer.
  • the biocidal composition comprises at least two proteases and at least one lipase, and a carrier comprising an alcohol and an acid, preferably an ethanol-based alcohol and a sulfonic acid.
  • the biocidal composition comprises a metalloprotease, a cysteine protease and a lipase, preferably an esterase or microbial lipase; and the composition also comprises a carrier comprising an alcohol and an acid, preferably an ethanol-based alcohol and a sulfonic acid.
  • the biocidal composition comprises a cysteine protease and a lipase, preferably an esterase or microbial lipase; and the composition also comprises a carrier comprising an alcohol and an acid, preferably an ethanol-based alcohol and a sulfonic acid.
  • the biocidal composition comprises at least two proteases and at least one lipase; and a carrier comprising at least one PEG glycol ether and at least one alkyl sulfate anionic detergent, preferably as described in statements above, and most preferably PEG- 10 tridecyl ether and sodium dodecyl sulfate.
  • the biocidal composition comprises a metalloprotease, a cysteine protease and a lipase, preferably an esterase or microbial lipase; and the composition also comprises a carrier comprising at least one PEG glycol ether and at least one alkyl sulfate anionic detergent, preferably as described in statements above, and most preferably PEG- 10 tridecyl ether and sodium dodecyl sulfate.
  • the biocidal composition comprises a cysteine protease and a lipase, preferably an esterase or microbial lipase; and the composition also comprises a carrier comprising at least one PEG glycol ether and at least one alkyl sulfate anionic detergent, preferably as described in statements above, and most preferably PEG- 10 tridecyl ether and sodium dodecyl sulfate.
  • a method of protecting a surface from microorganisms comprising the steps of:
  • the method according to the second aspect of the invention may, as appropriate, include any or all of the features described in relation to the biocidal composition of the first aspect of the invention.
  • the step of providing the biocidal composition may comprise the step of mixing a carrier with at least one protease selected from a serine protease, a metalloprotease and a cysteine protease, and at least one lipase selected from a phospholipase, an esterase and a microbial lipase.
  • the or each protease and lipase may be as defined and described above for the first aspect of the invention.
  • the biocidal composition may be applied onto glass, metal, ceramic, wooden plastic or textile surfaces. It has been found that the biocidal composition is able to substantially eliminate coronaviruses on most surfaces, including glass, metal, ceramic, wooden plastic or textile surfaces.
  • the textile surface may comprise cotton.
  • the biocidal composition may be applied onto the surface by spraying, wiping, dipping or by immersing the surface in the biocidal composition. In this way, the biocidal composition can be applied onto a variety of surfaces easily and quickly.
  • a product that comprises the biocidal composition according to the first aspect of the invention.
  • the product according to the third aspect of the invention may be include, as appropriate, any or all of the features described in relation to the biocidal composition of the first aspect of the invention.
  • the product may comprise a solid support soaked or treated with the biocidal composition.
  • the solid support may comprise a fabric sheet such as a wipe or cloth.
  • the fabric may be formed from natural or synthetic fibres.
  • an enzyme mixture as a biocide, the mixture comprising:
  • At least one protease selected from a serine protease, a metalloprotease and a cysteine protease
  • At least one lipase selected from a phospholipase, an esterase and a microbial lipase.
  • the use of the mixture according to the fourth aspect of the invention may include, as appropriate, any or all of the features described in relation to the first, second and third aspects of the invention.
  • the use may include using a composition of the first, second or third aspects of the invention.
  • the mixture may be used as a virucide.
  • the mixture may be used as a virucide against coronaviruses.
  • the mixture can be used as a virucide against Covid- 19, SARS-COV and MERS-COV.
  • the mixture may be used as a virucide against an enveloped virus.
  • the mixture may be used as a virucide against Influenza.
  • the mixture may be used as a virucide against a non-enveloped virus.
  • the mixture may be used as a virucide against Norovirus.
  • the protease may be a metalloprotease, serine protease or cysteine protease, or any combination thereof, and may be described above for the other aspects of the invention.
  • the protease may be a metalloprotease, which has been found to be particularly effective at killing coronaviruses.
  • the protease may be selected from PROMOD 439L (serine protease, specifically a subtilase), PROMOD 24L (metalloprotease from Bacillus subtilis') or PROMOD 950L (cysteine protease) or any combination thereof.
  • the protease may be present in a carrier.
  • the protease may be applied to the coronavirus in a carrier at a concentration of between 0.001 and 0.5 %wt.
  • the protease may be applied to the coronavirus as a spray, for example or may be applied as a liquid or aerosol.
  • the protease may be applied to a surface, which may be as defined and described above for other aspects of the invention.
  • the protease may be applied to the surface to kill, inhibit or disable coronavirus on the surface and/or which may contact the surface post-application of the protease.
  • proteases are effective at killing and inhibiting coronaviruses on surfaces, and that application of proteases on surfaces provides long-lasting prophylactic effect against coronaviruses (at least 16 hours).
  • the use may comprise two or more proteases, independently selected from a metalloprotease, serine protease or cysteine protease.
  • protease and lipase may be as described and defined hereinabove for the first aspect of the invention.
  • the protease may be selected from PROMOD 439L (serine protease, specifically a subtilase), PROMOD 24L (metalloprotease from Bacillus subtilis) or PROMOD 950L (cysteine protease) or any combination thereof.
  • the protease may be present in a carrier.
  • the protease may be applied to the coronavirus in a carrier at a concentration of between 0.001 and 0.1 %wt.
  • the lipase may be a phospholipase, esterase or microbial lipase.
  • the phospholipase may be LIPOMOD 699L or LIPOMOD 833L and/or the esterase may be LIPOMOD 34MDP all manufactured by Biocatalysts Limited, Unit 1, Cefn Coed, Parc Nantgarw, Edinburgh, CF157QQ, Wales, UK.
  • the lipase may be applied to the coronavirus in a carrier at a concentration of between 0.001 and 0.5 %wt.
  • the protease(s) and lipase(s) may be applied to the coronavirus in the same or separate compositions. In some embodiments the protease(s) and lipase(s) may be applied in a liquid composition, which may be applied as a spray or aerosol.
  • the protease and lipase may be applied to a surface, which may be as defined and described above for other aspects of the invention.
  • the protease and lipase may be applied to the surface to kill, inhibit or disable coronavirus on the surface and/or which may contact the surface post-application of the protease.
  • Figure 1 shows the results of a visual test for determining the activity of protease enzymes when dried on a surface
  • Figure 2 shows the results of a quantitative test for determining the activity of protease enzymes when dried on a surface
  • Figure 3 shows the results of a visual test for determining the activity of lipase enzymes when dried on a surface
  • Figure 4 shows the results of tests for determining the effectiveness of individual proteases and lipases in reducing coronavirus levels
  • Figure 5 shows the results of tests for determining the effectiveness of compositions comprising proteases and lipases in reducing coronavirus levels
  • Figure 6 shows the results of enzyme concentration optimisation experiments
  • Figure 7 shows the results of experiments for determining the effectiveness of a composition for reducing coronavirus levels on surface up to sixteen hours; and Figure 8 shows the results of a test for determining the effect of the carrier on the virucidal activity of a composition containing protease and lipase enzymes.
  • proteases and lipases described in the examples below were acquired from Biocatalysts Ltd.
  • Three proteases A: PROMOD 439L (serine protease, specifically a subtilase); B: PROMOD 24L (metalloprotease from Bacillus subtilis, 1.1 %wt. enzyme concentration); C: PROMOD 950L (cysteine protease, 3.4 %wt. enzyme concentration)) and three lipases (D: LIPOMOD 699L (phospholipase); E: LIPOMOD 833L (phospholipase); F: LIPOMOD 34MDP (microbial lipase/esterase, 76 %wt.
  • A PROMOD 439L (serine protease, specifically a subtilase)
  • B PROMOD 24L (metalloprotease from Bacillus subtilis, 1.1 %wt. enzyme concentration)
  • C PROMOD 950L (cysteine protease
  • Standard substrates used were 4-nitrophenyl propionate (Merck #N3377) and Anorogenic chymotrypsin substrate II (Merck # 230914-25MG). SteriKleen and SteriKleen concentrate were provided by Smarti Environmental Ltd, UK. Other suitable standards include 4- Methylumbelliferyl butyrate (Santa Cruz Biotechnology #sc-206912A).
  • FIP feline infectious peritonitis
  • Enzyme F was supplied as a powder and was prepared to 10 mg/mL in PBS. Enzymes A-F were mixed one part in 20 with either PBS, SteriKleen, or. A 250 pL sample was dried onto glass (laboratory cover slide) or plastic (lid of Starlab TipOne box). Enzymes were left to dry onto the surface and were incubated at 4 °C, room temperature (20-22 °C) or 37 °C as appropriate. For protease samples, chymotrypsin substrate II was added to the dried enzyme. For visual tests, 25 pL of 1 mM substrate in 4% v/v methanol/PBS was added.
  • a 143 base pair fragment of FIP DNA (bases 12,605 to 12,747 of FIP accession number KC461237) was prepared by IDT using the method of Desmerets et al. (2013) Veterinary Research, 44, 71. (Doi: 10.1186/1297-9716-44-71).
  • RNA was prepared from this using T7 RNA polymerase (NEB #M0251) following the manufacturer’s recommendations, and the parent DNA was removed using DNase I (NEB #MO3O3).
  • RNA was prepared from samples using the QIAamp Viral RNA Mini kit (Qiagen #52906) following the manufacturer’s recommendations.
  • RT-qPCR was performed on a Rotor-Gene Q qPCR machine (Qiagen).
  • the Luna Universal One-Step RT-qPCR kit (NEB #E3005) was used following the manufacturer’s recommendations, except that a final volume of 10 pL was used and all quantities reduced in proportion. 1 pL of RNA preparation was added to each sample.
  • the cycling conditions were:
  • 5.63 pL of each enzyme, 214 pL SteriKleen and 25 pL FIP were mixed and incubated at room temperature for 10 minutes.
  • the final concentrations selected were chosen to give the minimal surviving FIP at the 95 th percentile of the model.
  • the surfaces used were: plastic - the lid of a standard SBS microplate and glass - cover slides.
  • lipases D, E and F one part in 20
  • pNP-propionate was added to the glass.
  • the release of fluorophore was measured by imaging the slides in white light.
  • only lipase F showed significant activity with a standard substrate and that there was no loss of activity over four hours at 37 °C in SteriKleen.
  • Example 2 Capability of Individual Enzymes to Reduce Coronavirus Levels.
  • Feline infectious peritonitis (FIP) samples were added to an equal volume of PBS, SteriKleen, or SteriKleen supplemented with 5% enzymes (A-F). After 10 minutes RNA was prepared from the mix and the number of surviving virus particles enumerated by RT-qPCR. As best shown in Figure 4 enzymes B and F showed a strong effect while enzymes A, C, D and E showed a smaller but adequate apparent effect in reducing coronavirus levels.
  • Enzymes were tested in pairs to establish whether any enzyme combinations could lead to an enhanced coronavirus killing effect.
  • FIP samples were added to an equal volume of PBS, SteriKleen, or SteriKleen supplemented with 2.5% each of two enzymes. After 10 minutes RNA was prepared from the mix and the number of surviving virus particles enumerated by RT-qPCR.
  • Figure 5 is a graph showing the results of the enzyme pair tests. It can be seen that all combinations involving enzyme B gave good results, as expected from the individual enzyme results. However, enzyme C showed strong synergy with enzymes D and F and both combinations were effective in reducing corona virus levels and exhibited improved performance relative to enzymes C, D and F alone.
  • RNA samples were added to an equal volume of PBS, or SteriKleen supplemented with 0.125% each of proteases B and C, 0.25% of lipase F, or 0.125 % each of proteases B and C and 0.25 % of lipase F.
  • RNA was prepared from the mix and the number of surviving virus particles enumerated by RT-qPCR.
  • enzyme mixtures comprising 0.125% of proteases B and C, and 0.25% of lipase F show robust efficacy in that coronavirus levels could be reduced to less than 0.1%, even at low enzyme concentrations. Since only low enzyme concentrations are needed to obtain a good coronavirus killing effect, this has the added benefit that compositions comprising enzymes B, C and F are likely to be economic.
  • composition comprising SteriKleen, 0.125 % each of proteases B and C and 0.25 % of lipase F was tested to establish whether the composition could reduce and keep coronavirus levels low for up to 16 hours when applied onto plastic and glass surfaces.
  • 250 pL of enzyme/SteriKleen mix was applied to a surface and allowed to dry. After sixteen hours, FIP samples (25 pL) were added to the surface. After 10 minutes the FIP was recovered from the surface, RNA was prepared from the mix and the number of surviving virus particles enumerated by RT-qPCR.
  • Example 6 Quantitative suspension test for evaluation of virucidal activity against Influenza
  • a composition comprising an aqueous solution containing a Cirrus- 17 carrier (sodium lauryl sulfate, PEG- 10 tridecyl ether, and acrylate-styrene copolymer) and 0.022% of protease B, 0.068% of protease C and 0.0077 % of lipase F was tested for its activity against both Influenza and Norovirus.
  • Samples of the composition were either left neat or diluted by 50% in distilled water and were independently added to test suspensions of Influenza Virus H1N1 (VR-1638) and Murine Norovirus strain S99 Berlin in solutions of clean 0.3 g/L bovine albumin interfering substance.
  • the mixtures were maintained at 20°C ⁇ 1°C for a contact time of 5 mins ⁇ 10 s. At the end of this contact time, aliquots were taken; the virucidal action in these portions was immediately suppressed by a validated method (dilutions of the sample in ice-cold cell maintenance medium). The dilutions were transferred into cell culture units either using monolayer or cell suspension. Infectivity tests were done either by plaque test or quantal tests. After incubation, the titres of infectivity were calculated according to Spearman and Kaber or by plaque counting. Reduction of virus infectivity was calculated from differences of log virus titres before (virus control) and after treatment with the products.
  • Results for Influenza H1N1 are shown in Tables 1-3 below. As displayed in Tables 1-3, the composition achieved a greater than 4-log reduction against Influenza HINT. The product suppression control also showed a ⁇ 0.5-log reduction in viral titre. The results also showed a 4-log difference between the cytotoxicity level and viral titre. Accordingly, the composition was shown to be greatly effective against Influenza H1N1.
  • results for Murine Norovirus are shown in Tables 4-6 below. As displayed in Tables 4-6, the composition also achieved a high 3.92-log reduction when neat and 2.67-log reduction when at 50% dilution against Murine Norovirus, indicating good efficacy against the virus.
  • Example 7 Test to evaluate the effect of the carrier on biocidal performance
  • RNA samples were independently added to equal volumes of SteriKleen; SteriKleen supplemented with 0.011% of protease B, 0.034% of protease C, and 0.0038% of lipase F; an aqueous solution containing the same mixture of enzymes (same concentration as previous sample) and also a Cirrus- 17 carrier at a concentration 2-times that employed in Example 6 above; an aqueous solution containing the same mixture of enzymes (same concentration as previous sample) and also a Cirrus- 17 carrier at the same concentration as that employed in Example 6; an aqueous solution containing the same mixture of enzymes (same concentration as previous sample) and also a Cirrus- 17 carrier at a concentration 0.5-times that employed in Example 6; and an aqueous solution containing the same mixture of enzymes (same concentration as previous sample) and also a Cirrus- 17 carrier at a concentration 0.25-times that employed in Example 6. After 5 minutes, RNA was prepared from the mixtures
  • the results of the above tests demonstrate that the addition of proteases and lipases to a SteriKleen cleaning solution make it capable of breaking down and killing coronaviruses.
  • the results also show good activity of compositions containing proteases and lipases and a carrier comprising detergents, particularly a combination of an anionic detergent and a non-ionic detergent, and preferably also a film-forming polymer, against enveloped and non-enveloped viruses, including Influenza and Norovirus.
  • Enzyme mixtures comprising metalloproteases, cysteine proteases and esterases or microbial lipases were particularly effective, but very good biocidal activity was also observed when SteriKleen was supplemented with one protease and one lipase.
  • enzyme mixtures comprising a metalloprotease and a phospholipase; a cysteine protease and a phospholipase or a cysteine protease and an esterase or microbial lipase exhibited very good biocidal performance. It has also been demonstrated that robust efficacy in eliminating coronaviruses at surfaces for up to sixteen hours even when the concentration of enzymes in the composition is low. Therefore, the biocidal compositions offer a cost-effective solution for protecting the surfaces from microorganisms such as coronaviruses over extended periods of time.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)

Abstract

L'invention concerne une composition biocide, comprenant : - au moins une protéase choisie parmi une sérine protéase, une métalloprotéase et une cystéine protéase ; et - au moins une lipase choisie parmi une phospholipase, une estérase et une lipase microbienne ; et un entraîneur.
PCT/GB2021/052856 2020-11-06 2021-11-04 Composition biocide WO2022096881A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21806023.4A EP4240161A1 (fr) 2020-11-06 2021-11-04 Composition biocide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2017605.3A GB202017605D0 (en) 2020-11-06 2020-11-06 biocidal Composition
GB2017605.3 2020-11-06

Publications (1)

Publication Number Publication Date
WO2022096881A1 true WO2022096881A1 (fr) 2022-05-12

Family

ID=74045988

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2021/052856 WO2022096881A1 (fr) 2020-11-06 2021-11-04 Composition biocide

Country Status (3)

Country Link
EP (1) EP4240161A1 (fr)
GB (1) GB202017605D0 (fr)
WO (1) WO2022096881A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031554A2 (fr) * 2004-09-10 2006-03-23 Novozymes North America, Inc. Procedes permettant de detruire, de reduire, d'eliminer ou d'empecher la formation d'un film biologique
WO2008013747A2 (fr) * 2006-07-24 2008-01-31 Genencor International, Inc. Prévention et suppression enzymatique de biofilms
WO2009118375A2 (fr) * 2008-03-26 2009-10-01 Novozymes A/S Compositions stabilisées d’enzymes liquides
WO2010069812A2 (fr) * 2008-12-18 2010-06-24 Henkel Ag & Co. Kgaa Désinfection virale de textiles et de surfaces dures
EP3344765A1 (fr) * 2015-08-28 2018-07-11 Unilever NV Composition détergente liquide comprenant une lipase et une protéase
WO2019135003A1 (fr) * 2018-01-08 2019-07-11 Enzymatica Ab Peptides présentant une activité de protéase destinés à être utilisés dans le traitement ou la prévention d'une infection à coronavirus
US10932505B1 (en) * 2020-09-10 2021-03-02 Mandy Jane Ward Enzyme-enhanced anti-viral fabrics

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031554A2 (fr) * 2004-09-10 2006-03-23 Novozymes North America, Inc. Procedes permettant de detruire, de reduire, d'eliminer ou d'empecher la formation d'un film biologique
WO2008013747A2 (fr) * 2006-07-24 2008-01-31 Genencor International, Inc. Prévention et suppression enzymatique de biofilms
WO2009118375A2 (fr) * 2008-03-26 2009-10-01 Novozymes A/S Compositions stabilisées d’enzymes liquides
WO2010069812A2 (fr) * 2008-12-18 2010-06-24 Henkel Ag & Co. Kgaa Désinfection virale de textiles et de surfaces dures
EP3344765A1 (fr) * 2015-08-28 2018-07-11 Unilever NV Composition détergente liquide comprenant une lipase et une protéase
WO2019135003A1 (fr) * 2018-01-08 2019-07-11 Enzymatica Ab Peptides présentant une activité de protéase destinés à être utilisés dans le traitement ou la prévention d'une infection à coronavirus
US10932505B1 (en) * 2020-09-10 2021-03-02 Mandy Jane Ward Enzyme-enhanced anti-viral fabrics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMTMANN ANETTE ET AL: "Virucidal effects of various agents-including protease-against koi herpesvirus and viral haemorrhagic septicaemia virus", JOURNAL OF FISH DISEASES, vol. 43, no. 2, 26 February 2020 (2020-02-26), GB, pages 185 - 195, XP055823289, ISSN: 0140-7775, DOI: 10.1111/jfd.13106 *
BERTRAM STEPHANIE ET AL: "Cleavage and Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by Human Airway Trypsin-Like Protease", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 85, no. 24, 30 November 2011 (2011-11-30), pages 13363 - 13372, XP009512575, ISSN: 0022-538X, DOI: 10.1128/JVI.05300-11 *

Also Published As

Publication number Publication date
EP4240161A1 (fr) 2023-09-13
GB202017605D0 (en) 2020-12-23

Similar Documents

Publication Publication Date Title
US7217684B2 (en) Process and composition for cleaning medical instruments
AU2009251192A1 (en) Anti-viral and anti-bacterial cleaning composition
JP6732454B2 (ja) 洗浄殺菌剤組成物
WO2019241614A1 (fr) Compositions comprenant une enzyme et des composés d'ammonium quaternaire
JP6324018B2 (ja) 血液分析器を洗浄するためのホルムアルデヒドを含まない洗浄剤組成物およびその使用法
KR100874048B1 (ko) 살생물제 보호시스템
JPH0562920B2 (fr)
JP2014012860A5 (fr)
JP6444104B2 (ja) 洗濯用液体殺菌洗浄剤組成物およびそれを用いた繊維品の非エンベロープウイルスの不活化方法
EP4240161A1 (fr) Composition biocide
JP5198771B2 (ja) 抗ウイルス性および抗菌性の清浄用組成物
US11370998B2 (en) Synergistic cellulase-surfactant interactions for degradation of bacterial cellulose
AU2009243922B2 (en) Instrument cleaner
CA3012079C (fr) Composition desinfectante
US20080260788A1 (en) Skin Cleaning Composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21806023

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021806023

Country of ref document: EP

Effective date: 20230606